| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 2,380 | 2,900 | 3,280 | 3,660 | 3,240 |
| Sales Growth | -17.93% | -11.59% | -10.38% | +12.96% | -16.92% |
| Net Income | -1,350 | -430 | -200 | -160 | -110 |
| Net Income Growth | -213.95% | -115.00% | -25.00% | -45.46% | -144.00% |
Radnostix Inc (INIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Radnostix Inc. manufactures a wide range of radioisotope focused products. The company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. It also manufactures Cobalt-60 sealed source products. Radnostix Inc., formerly known as International Isotopes Inc., is based in IDAHO FALLS, Idaho.
Fiscal Year End Date: 12/31